Alexander Kastner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexander Kastner has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Christian R. Kowol
Institute of Inorganic Chemistry Faculty of Chemistry University of Vienna Vienna Austria
7 shared publications - Petra Heffeter
Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8A, Vienna 1090, Austria
6 shared publications - Bernhard Klaus Keppler
Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria
5 shared publications Josef Mayr
Faculty of Chemistry Institute of Inorganic Chemistry University of Vienna Waehringer Strasse 42 1090 Vienna Austria
3 shared publicationsAlexander Roller
Faculty of Chemistry Institute of Inorganic Chemistry University of Vienna Waehringer Strasse 42 1090 Vienna Austria
2 shared publicationsBernhard K. Keppler
University of Vienna, Faculty of Chemistry, Institute of Inorganic Chemistry, Waehringer Str. 42, 1090 Vienna, Austria
2 shared publications
Latest Publications
- Open Access
- 6 December 2023
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 11 (2) , 534-548
Stepwise optimization of tumor-targeted dual-action platinum( iv )-gemcitabine prodrugs
An albumin-binding cisplatin( iv )-gemcitabine complex was step-by-step improved based on stability, reduction, albumin-binding and in vivo data yielding a carboplatin( iv ) complex with distinctly improved overall survival and anticancer activity.
- 6 December 2023
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 11 (2) , 534-548
Open AccessStepwise optimization of tumor-targeted dual-action platinum( iv )-gemcitabine prodrugs
An albumin-binding cisplatin( iv )-gemcitabine complex was step-by-step improved based on stability, reduction, albumin-binding and in vivo data yielding a carboplatin( iv ) complex with distinctly improved overall survival and anticancer activity.
- Open Access
- 13 October 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (46) , e202311468
Einbau von (Bioaktiven) Äquatorialen Liganden in Platin(IV)‐Komplexe
Platin(IV)‐Prodrugs sind aufgrund ihrer erhöhten Tumorselektivität und geringeren Nebenwirkungen äußerst interessante Alternativen zu Platin(II)‐Antitumortherapeutika. Im Gegensatz zur gängigen Theorie haben wir kürzlich beobachtet, dass äquatoriale Liganden von z. B. Oxaliplatin(IV)‐Komplexen unter Bildung von [(DACH)Pt(OH eq ) 2 (OAc ax ) 2 ] hydrolysiert werden können. In der hier vorgestellten Arbeit untersuchten wir die Reaktivität und synthetische Verwendbarkeit dieses Komplexes, als Vorstufe für die Entwicklung neuartiger Platin(IV)‐Komplexe, welche mit herkömmlichen Methoden nicht zugänglich sind. Tatsächlich war es möglich die äquatorialen Hydroxidoliganden z. B. durch ein oder zwei monodentate Biotin‐Liganden, die unter Standardmethoden oxidiert werden würden, zu ersetzen. Die gebildeten Komplexe erwiesen sich als sehr stabil und zeigten auch nach der Reduktion eine langsame Ligandenfreisetzung, eine ideale Eigenschaft für lang zirkulierende zielgerichtete Strategien. Daraufhin wurden zwei Platin(IV)‐Komplexe mit äquatorialen Maleimiden, für die Bindung an Serumalbumin als natürlichen Nanocarrier, synthetisiert. Die Komplexe zeigten im Vergleich zu Oxaliplatin eine stark verlängerte Plasmahalbwertszeit und eine deutlich verbesserte Antitumoraktivität in vivo. Zusammenfassend ermöglicht diese neu entwickelte Syntheseplattform den einfachen und gezielten Einbau äquatorialer Liganden in Platin(IV)‐Komplexe. Des Weiteren können verschiedene (bioaktive) Einheiten koordiniert werden, wodurch sogar zielgerichtete dreifach‐wirksame Platin(IV)‐Prodrugs mit nur einem Platinzentrum möglich wären.
- 13 October 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (46) , e202311468
Open AccessEinbau von (Bioaktiven) Äquatorialen Liganden in Platin(IV)‐Komplexe
Platin(IV)‐Prodrugs sind aufgrund ihrer erhöhten Tumorselektivität und geringeren Nebenwirkungen äußerst interessante Alternativen zu Platin(II)‐Antitumortherapeutika. Im Gegensatz zur gängigen Theorie haben wir kürzlich beobachtet, dass äquatoriale Liganden von z. B. Oxaliplatin(IV)‐Komplexen unter Bildung von [(DACH)Pt(OH eq ) 2 (OAc ax ) 2 ] hydrolysiert werden können. In der hier vorgestellten Arbeit untersuchten wir die Reaktivität und synthetische Verwendbarkeit dieses Komplexes, als Vorstufe für die Entwicklung neuartiger Platin(IV)‐Komplexe, welche mit herkömmlichen Methoden nicht zugänglich sind. Tatsächlich war es möglich die äquatorialen Hydroxidoliganden z. B. durch ein oder zwei monodentate Biotin‐Liganden, die unter Standardmethoden oxidiert werden würden, zu ersetzen. Die gebildeten Komplexe erwiesen sich als sehr stabil und zeigten auch nach der Reduktion eine langsame Ligandenfreisetzung, eine ideale Eigenschaft für lang zirkulierende zielgerichtete Strategien. Daraufhin wurden zwei Platin(IV)‐Komplexe mit äquatorialen Maleimiden, für die Bindung an Serumalbumin als natürlichen Nanocarrier, synthetisiert. Die Komplexe zeigten im Vergleich zu Oxaliplatin eine stark verlängerte Plasmahalbwertszeit und eine deutlich verbesserte Antitumoraktivität in vivo. Zusammenfassend ermöglicht diese neu entwickelte Syntheseplattform den einfachen und gezielten Einbau äquatorialer Liganden in Platin(IV)‐Komplexe. Des Weiteren können verschiedene (bioaktive) Einheiten koordiniert werden, wodurch sogar zielgerichtete dreifach‐wirksame Platin(IV)‐Prodrugs mit nur einem Platinzentrum möglich wären.
- Open Access
- 13 October 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (46) , e202311468
Insertion of (Bioactive) Equatorial Ligands into Platinum(IV) Complexes
Platinum(IV) prodrugs are highly interesting alternatives to platinum(II) anticancer therapeutics due to their increased tumor selectivity and reduced side effects. In contrast to the established theory, we recently observed that the equatorial ligand(s) of e.g. oxaliplatin(IV) complexes can be hydrolyzed with formation of [(DACH)Pt(OH eq ) 2 (OAc ax ) 2 ]. In the work presented here, we investigated the reactivity and synthetic usability of this complex to be exploited as a precursor for the development of novel platinum(IV) complexes, not able to be synthesized by conventional protocols. Indeed, we could substitute the equatorial hydroxido ligand(s) e.g. by one or two monodentate biotin ligands (which would be oxidized under standard methods). The formed complexes turned out to be very stable with slow ligand release after reduction, ideal for long‐circulating tumor‐targeting strategies. Therefore, two platinum(IV) complexes with equatorial maleimides, capable of exploiting serum albumin as a natural nanocarrier, were synthesized as well. The complexes showed massively prolonged plasma half‐life and distinctly improved anticancer activity in vivo compared to oxaliplatin. Taken together, the newly developed synthetic platform allows the simple and specific insertion of equatorial ligands into platinum(IV) complexes. This will enable the attachment of three different (bioactive) moieties generating targeted triple‐action platinum(IV) prodrugs within one single platinum complex.
- 13 October 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (46) , e202311468
Open AccessInsertion of (Bioactive) Equatorial Ligands into Platinum(IV) Complexes
Platinum(IV) prodrugs are highly interesting alternatives to platinum(II) anticancer therapeutics due to their increased tumor selectivity and reduced side effects. In contrast to the established theory, we recently observed that the equatorial ligand(s) of e.g. oxaliplatin(IV) complexes can be hydrolyzed with formation of [(DACH)Pt(OH eq ) 2 (OAc ax ) 2 ]. In the work presented here, we investigated the reactivity and synthetic usability of this complex to be exploited as a precursor for the development of novel platinum(IV) complexes, not able to be synthesized by conventional protocols. Indeed, we could substitute the equatorial hydroxido ligand(s) e.g. by one or two monodentate biotin ligands (which would be oxidized under standard methods). The formed complexes turned out to be very stable with slow ligand release after reduction, ideal for long‐circulating tumor‐targeting strategies. Therefore, two platinum(IV) complexes with equatorial maleimides, capable of exploiting serum albumin as a natural nanocarrier, were synthesized as well. The complexes showed massively prolonged plasma half‐life and distinctly improved anticancer activity in vivo compared to oxaliplatin. Taken together, the newly developed synthetic platform allows the simple and specific insertion of equatorial ligands into platinum(IV) complexes. This will enable the attachment of three different (bioactive) moieties generating targeted triple‐action platinum(IV) prodrugs within one single platinum complex.
- Open Access
- 28 June 2023
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 10 (14) , 4126-4138
Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs
Platinum(IV) prodrugs are a promising class of anticancer agents designed to overcome the limitations of conventional platinum(II) therapeutics. In this work, we present oxaliplatin(IV)-based complexes, which upon reduction, release acetylsalicylic acid (aspirin), known for its antitumor activity against colon cancer and currently investigated in combination with oxaliplatin in a phase III clinical study. Comparison with a recently reported cisplatin analog (asplatin) revealed a massive increase in reduction stability for the oxaliplatin complex in mouse serum. This was in line with the cell culture data indicating the desired prodrug properties for the newly synthesized complex. For in vivo studies, a new derivative containing an albumin-binding maleimide unit was synthesized. Indeed, distinctly longer plasma half-life as well as higher tumor accumulation in comparison to asplatin and oxaliplatin were observed, also leading to significantly higher antitumor activity and overall survival of CT26 tumor-bearing mice.
- 28 June 2023
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 10 (14) , 4126-4138
Open AccessTumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs
Platinum(IV) prodrugs are a promising class of anticancer agents designed to overcome the limitations of conventional platinum(II) therapeutics. In this work, we present oxaliplatin(IV)-based complexes, which upon reduction, release acetylsalicylic acid (aspirin), known for its antitumor activity against colon cancer and currently investigated in combination with oxaliplatin in a phase III clinical study. Comparison with a recently reported cisplatin analog (asplatin) revealed a massive increase in reduction stability for the oxaliplatin complex in mouse serum. This was in line with the cell culture data indicating the desired prodrug properties for the newly synthesized complex. For in vivo studies, a new derivative containing an albumin-binding maleimide unit was synthesized. Indeed, distinctly longer plasma half-life as well as higher tumor accumulation in comparison to asplatin and oxaliplatin were observed, also leading to significantly higher antitumor activity and overall survival of CT26 tumor-bearing mice.
- Open Access
- 27 October 2020
- Published by Wiley in Chemistry – A European Journal
- Vol. 26 (68) , 15867-15870
Improving the Stability of Maleimide–Thiol Conjugation for Drug Targeting
Maleimides are essential compounds for drug conjugation reactions via thiols to antibodies, peptides and other targeting units. However, one main drawback is the occurrence of thiol exchange reactions with, for example, glutathione resulting in loss of the targeting ability. A new strategy to overcome such retro‐Michael exchange processes of maleimide–thiol conjugates by stabilization of the thiosuccinimide via a transcyclization reaction is presented. This reaction enables the straightforward synthesis of stable maleimide–thiol adducts essential in drug‐conjugation applications.
- 27 October 2020
- Published by Wiley in Chemistry – A European Journal
- Vol. 26 (68) , 15867-15870
Open AccessImproving the Stability of Maleimide–Thiol Conjugation for Drug Targeting
Maleimides are essential compounds for drug conjugation reactions via thiols to antibodies, peptides and other targeting units. However, one main drawback is the occurrence of thiol exchange reactions with, for example, glutathione resulting in loss of the targeting ability. A new strategy to overcome such retro‐Michael exchange processes of maleimide–thiol conjugates by stabilization of the thiosuccinimide via a transcyclization reaction is presented. This reaction enables the straightforward synthesis of stable maleimide–thiol adducts essential in drug‐conjugation applications.
- Open Access
- 14 March 2019
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 58 (22) , 7464-7469
A Dogma in Doubt: Hydrolysis of Equatorial Ligands of PtIV Complexes under Physiological Conditions
Due to their high kinetic inertness and consequently reduced side reactions with biomolecules, PtIV complexes are considered to define the future of anticancer platinum drugs. The aqueous stability of a series of biscarboxylato PtIV complexes was studied under physiologically relevant conditions. Unexpectedly and in contrast to the current chemical understanding, especially oxaliplatin and satraplatin complexes underwent fast hydrolysis in equatorial position (even in cell culture medium and serum). Notably, the resulting hydrolysis products strongly differ in their reduction kinetics, a crucial parameter for the activation of PtIV drugs, which also changes the anticancer potential of the compounds in cell culture. The discovery that intact PtIV complexes can hydrolyze at equatorial position contradicts the dogma on the general kinetic inertness of PtIV compounds and needs to be considered in the screening and design for novel platinum‐based anticancer drugs.
- 14 March 2019
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 58 (22) , 7464-7469
Open AccessA Dogma in Doubt: Hydrolysis of Equatorial Ligands of PtIV Complexes under Physiological Conditions
Due to their high kinetic inertness and consequently reduced side reactions with biomolecules, PtIV complexes are considered to define the future of anticancer platinum drugs. The aqueous stability of a series of biscarboxylato PtIV complexes was studied under physiologically relevant conditions. Unexpectedly and in contrast to the current chemical understanding, especially oxaliplatin and satraplatin complexes underwent fast hydrolysis in equatorial position (even in cell culture medium and serum). Notably, the resulting hydrolysis products strongly differ in their reduction kinetics, a crucial parameter for the activation of PtIV drugs, which also changes the anticancer potential of the compounds in cell culture. The discovery that intact PtIV complexes can hydrolyze at equatorial position contradicts the dogma on the general kinetic inertness of PtIV compounds and needs to be considered in the screening and design for novel platinum‐based anticancer drugs.
- Open Access
- 14 March 2019
- Published by Wiley in Angewandte Chemie
- Vol. 131 (22) , 7542-7547
Zweifel an einem Dogma: Hydrolyse äquatorialer Liganden von PtIV‐Komplexen unter physiologischen Bedingungen
PtIV‐Komplexe gelten aufgrund ihrer hohen kinetischen Inertheit und der folglich reduzierten Nebenreaktionen mit Biomolekülen als die Zukunft der Platintherapeutika. In dieser Arbeit wurde unter physiologisch relevanten Bedingungen die Stabilität einer Reihe von PtIV‐Biscarboxylatokomplexen in wässriger Lösung untersucht. Entgegen des derzeitigen chemischen Kenntnisstandes zeigten (sogar in Zellkulturmedium und Serum) vor allem Oxaliplatin‐ und Satraplatinkomplexe eine schnelle äquatoriale Hydrolyse. Die gebildeten Hydrolyseprodukte unterscheiden sich besonders stark in ihrer Reduktionskinetik, einem entscheidenden Parameter für die Aktivierung von PtIV‐Medikamenten, welcher auch mit der zytotoxischen Effizienz der Verbindungen in der Zellkultur korreliert. Die Entdeckung, dass intakte PtIV‐Komplexe an äquatorialer Position hydrolysiert werden können, widerspricht dem Dogma hinsichtlich der allgemeinen kinetischen Inertheit von PtIV‐Verbindungen und muss beim Screening und der Entwicklung neuer platin‐basierter Krebsmedikamente berücksichtigt werden.
- 14 March 2019
- Published by Wiley in Angewandte Chemie
- Vol. 131 (22) , 7542-7547
Open AccessZweifel an einem Dogma: Hydrolyse äquatorialer Liganden von PtIV‐Komplexen unter physiologischen Bedingungen
PtIV‐Komplexe gelten aufgrund ihrer hohen kinetischen Inertheit und der folglich reduzierten Nebenreaktionen mit Biomolekülen als die Zukunft der Platintherapeutika. In dieser Arbeit wurde unter physiologisch relevanten Bedingungen die Stabilität einer Reihe von PtIV‐Biscarboxylatokomplexen in wässriger Lösung untersucht. Entgegen des derzeitigen chemischen Kenntnisstandes zeigten (sogar in Zellkulturmedium und Serum) vor allem Oxaliplatin‐ und Satraplatinkomplexe eine schnelle äquatoriale Hydrolyse. Die gebildeten Hydrolyseprodukte unterscheiden sich besonders stark in ihrer Reduktionskinetik, einem entscheidenden Parameter für die Aktivierung von PtIV‐Medikamenten, welcher auch mit der zytotoxischen Effizienz der Verbindungen in der Zellkultur korreliert. Die Entdeckung, dass intakte PtIV‐Komplexe an äquatorialer Position hydrolysiert werden können, widerspricht dem Dogma hinsichtlich der allgemeinen kinetischen Inertheit von PtIV‐Verbindungen und muss beim Screening und der Entwicklung neuer platin‐basierter Krebsmedikamente berücksichtigt werden.